arrow
A

Amanda Swain

The Institute of Cancer Research
H指数:36
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

IAP antagonist tolinapant (ASTX660) in combination with pembrolizumab in advanced solid tumors: a phase I trial

IAP拮抗剂托利那潘特(ASTX660)联合帕博利珠单抗治疗晚期实体瘤:一项I期临床试验

2026-09-300
OA
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer

阐明靶向MCL1的分子分层单药及联合治疗策略,以治疗致命性前列腺癌

2025-10-080
OAAI
Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
2024-02-272
OAAI
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
2021-02-0186
OAAI
Targeting the p300/CBP Axis in Lethal Prostate Cancer

靶向p300/CBP轴在致死性前列腺癌中的作用

2021-01-11152
OA
Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer
2019-05-0161
OAAI
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids
2019-04-1581
OAAI
Targeting the bromodomain and extra-terminal (BET) family proteins and beyond in metastatic castration-resistant prostate cancer (mCRPC): Overcoming aberrant androgen receptor (AR) signaling.
2018-08-140
PRE
Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)
2018-07-01117
OAAI
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
2018-05-10335
OAAI